This page shows the latest axial spondyloarthritis news and features for those working in and with pharma, biotech and healthcare.
The IL-17 inhibitor has continued to outpace expectations, and has been stacking up indications, with the most recent filing for approval in non-radiographic axial spondyloarthritis.
These results are a blow for Novartis, especially after the resounding positive results it unveiled at the beginning of the month for Cosentyx in non-radiographic axial spondyloarthritis (nr-axSpA).
This could be helped with a new approval in non-radiographic axial spondyloarthritis (nr-axSpA) – Novartis reported positive phase 3 data for Consentyx in this indication earlier this month, as it
Scopes approval in non-radiographic axial spondyloarthritis. Novartis has unveiled more positive phase 3 data for Cosentyx, this time in patients with non-radiographic axial spondyloarthritis (nr-axSpA).
The new data comes from the Swiss pharma’s PREVENT trial, in patients with non-radiographic axial spondyloarthritis (nr-axSpA). ... earlier in axial spondyloarthritis,” said John Tsai (pictured below), head of global drug development and chief
The pilot project has so far been added to two clinical trials, a study of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis and one of Cialis (tadalafil) in pediatric patients with
More from news
Approximately 2 fully matching, plus 13 partially matching documents found.
Overview of spondyloarthritis patient profiles and treatment pathways. Spondyloarthritis is the name for a family of arthritis causing inflammatory rheumatic diseases; including axial spondyloarthritis, psoriatic arthritis and akylosing spondylitis,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...